TSLA
Tesla
-- 421.060 NVDA
NVIDIA
-- 134.700 PLTR
Palantir
-- 80.550 AMD
Advanced Micro Devices
-- 119.210 QUBT
Quantum Computing
-- 17.620 
NEWS
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance from the U.S. FDA and is expected to begin Phase 1 trials in Q1 2025. The antibody targets mesothelin, prevalent in cancers like ovarian, lung, and pancreatic. Context plans to use its existing cash reserves to fund the acquisition and initial clinical trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment